A document submitted by Pfizer-BioNTech as part of its Biological License Application (BLA) for the Covid vaccine to the FDA, entitled “5.3.6 Cumulative analysis of post-authorization adverse event reports of pf-07302048 (bnt162b2) received through 28-feb-2021”, looked at adverse event reports from Dec. 1, 2020, through Feb. 28, 2021 from 63 countries. Most reports came from the United States and the United Kingdom.
Read More.